Magle Chemoswed Holding OM:MAGLE Stock Report

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Group announced that the first patients have been included in a post-market clinical follow-up study of SmartPAN® an innovative first-in-class medical device developed to improve the outcome of pancreatic surgery. The study aims to further demonstrate the effectiveness of SmartPAN® in detecting pancreatic fluid leakage, which if left undetected can lead to significant postoperative side effects. The study results have the potential to support reimbursement applications in Europe and facilitate marketing approvals in other parts of the world. SmartPAN® is a patented first-in-class medical device developed jointly with the University of Heidelberg and Magle Group. SmartPAN®is based on Magle Group's patented bio-compatible and bio-degradable microsphere technology (DSM). The product is approved for medical use in Europe since 2021. Postoperative pancreatic fistula (POPF) is a common and potentially life-threatening complication after pancreatic surgery. POPF can develop due to leaking pancreatic fluid. SmartPAN® acts as an intraoperative indicator of leakage by providing a near-immediate and accurate colour indication when in contact with the pancreatic fluid. SmartPAN® provides a less complicated approach to identifying and localising pancreatic leaks in order to benefit patient outcomes. The post-market clinical follow-up (PMCF) study is being conducted at the University Hospital of Heidelberg by (surgeon names), and will enroll up to 36 patients. The final results are expected in late 2022 or early 2023. A PMCF study is aimed at keeping up-to-date on the security and effectiveness of a medical device approved in the EU.

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

The Magle Group announced that it will commence its post market clinical study in collaboration with the University of Heidelberg, Medical Faculty a world leading center in pancreatic surgery. SmartPAN® is a patented first-in-class medical device developed jointly with the University of Heidelberg and Magle Chemoswed AB. SmartPAN® is based on the patented bio-compatible and bio-degradable microsphere technology (DSM) owned by Magle Chemoswed.Postoperative pancreatic fistula (POPF) is a common and potentially life-threatening complication after pancreatic surgery. POPF can develop due to leaking pancreatic fluid. SmartPAN® acts as an intraoperative indicator of leakage by providing a near-immediate and accurate colour indication when in contact with the pancreatic fluid. SmartPAN® provides a less complicated approach to identifying and localising pancreatic leaks that benefits patient outcomes.

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Investor sentiment deteriorated over the past week

After last week's 17% share price decline to kr22.20, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 49x in the Life Sciences industry in Sweden. Total loss to shareholders of 44% over the past year.